Research shows that PARP inhibitors cause 85.61% of reported side effects in ovarian cancer patients, with most problems appearing within 30 days of starting treatment. According to Gram Research analysis of over 200,000 FDA safety reports, different drugs cause different warning signs: PARP inhibitors commonly cause vitamin D deficiency and nighttime urination, bevacizumab causes stomach and intestinal problems, and immunotherapy drugs show serious complications like cancer progression. Combining drugs creates additional risks like lung inflammation and blood disorders.
Researchers analyzed over 200,000 reports of side effects from ovarian cancer medications to understand which drugs cause the most problems. According to Gram Research analysis, they found that PARP inhibitors (a type of targeted therapy) were involved in most reports, followed by bevacizumab and immunotherapy drugs. The study identified specific warning signs doctors should watch for with each medication, like lung problems when combining certain drugs, or stomach issues with bevacizumab. Most side effects appeared within the first month of treatment. This information helps doctors better prepare patients and catch problems early.
Key Statistics
A 2026 analysis of 209,920 adverse event reports from 33,538 ovarian cancer patients found that PARP inhibitors accounted for 85.61% of reported side effects, with bevacizumab causing 11.42% and immunotherapy drugs causing less than 3% combined.
Research shows that 85% of side effects from ovarian cancer medications were reported within 30 days of starting treatment, indicating that the first month is the critical monitoring period for catching problems early.
A pharmacovigilance study of ovarian cancer drug safety found that combining bevacizumab with PARP inhibitors created new warning signs including interstitial lung disease and myelodysplastic syndrome that weren’t as prominent with either drug alone.
Among 157,470 reports of PARP inhibitor side effects in ovarian cancer patients, the most common problems were vitamin D deficiency, nighttime urination, and unusual energy changes, suggesting these warrant routine monitoring.
The Quick Take
- What they studied: Which side effects happen most often in ovarian cancer patients taking newer cancer-fighting drugs, and when do these side effects typically appear?
- Who participated: 33,538 ovarian cancer patients who reported side effects from cancer medications between 2014 and 2025 in the FDA’s official safety database
- Key finding: PARP inhibitors caused 85.61% of reported side effects, with most problems showing up within 30 days of starting the medication. Different drug combinations created different warning signs.
- What it means for you: If you’re taking ovarian cancer medication, knowing the most common side effects helps you recognize problems early and talk to your doctor. However, this study counts reports, not proven causes, so individual experiences vary greatly.
The Research Details
Researchers looked at a massive database called FAERS (the FDA’s Adverse Event Reporting System) that collects reports of medication side effects from doctors, patients, and pharmacists. They examined over 200,000 reports from ovarian cancer patients who took four main types of newer cancer drugs: PARP inhibitors, bevacizumab, PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors. Instead of doing a new experiment, they used statistical methods to find patterns in existing reports—basically looking for which side effects appeared more often than expected with each drug.
The researchers used three different statistical approaches to spot safety signals (warning signs). This is like having three different detectives look at the same evidence to make sure they all agree on what’s suspicious. They tracked when side effects were reported, what type of side effect occurred, and whether certain drug combinations created different problems than single drugs alone.
This approach is valuable because it captures real-world experiences from thousands of patients rather than just laboratory studies. It’s fast—researchers can spot emerging safety problems quickly instead of waiting years for traditional research. However, it shows what people reported, not necessarily what the drugs caused, since patients taking cancer medications often have multiple health issues.
The study’s strength is its huge sample size and use of multiple statistical methods to confirm findings. The main limitation is that FAERS reports don’t prove a drug caused a side effect—they just show that both happened. Some side effects might be from cancer itself, other medications, or other health conditions. The study also can’t tell us how common these side effects are in the overall population, only that they were reported.
What the Results Show
PARP inhibitors dominated the reports, accounting for 85.61% of all adverse events (157,470 reports). The most commonly reported problems with PARP inhibitors were unusual energy increases, low vitamin D levels, nighttime urination, patients intentionally taking less medication than prescribed, increased hunger, and brain tumors. Bevacizumab, which works differently than PARP inhibitors, showed a completely different pattern of problems: stomach perforation (a hole in the digestive tract), protein in urine, intestinal perforation, and blood clots.
Immunotherapy drugs (PD-1, PD-L1, and CTLA-4 inhibitors) together made up only 3% of reports but showed serious problems including off-label use, death, and cancer progression. When doctors combined bevacizumab with PARP inhibitors, new warning signs appeared: lung inflammation (interstitial lung disease), blood cell disorders, and bone marrow problems.
Timing was important: most side effects were reported within 30 days of starting medication, suggesting doctors and patients notice problems quickly. This early detection window is crucial for patient safety.
The study found that combination therapy (using two drugs together) created different safety patterns than single drugs alone. Bevacizumab combined with PARP inhibitors showed serious blood-related problems that weren’t as prominent with either drug alone. The researchers also noted that some reported side effects might reflect how doctors use medications in real practice—for example, ‘intentional underdose’ with PARP inhibitors might indicate patients struggling with side effects and taking less medication without telling their doctor.
This study provides a comprehensive safety overview that complements clinical trial data. While clinical trials test drugs in controlled settings with selected patients, this real-world analysis captures what happens when thousands of diverse patients take these medications. Previous research has identified some of these side effects individually, but this study systematically compares safety profiles across multiple drug classes used for the same cancer.
The biggest limitation is that FAERS reports don’t prove causation—they only show that a side effect was reported while someone was taking a drug. Some reported problems might be coincidental or caused by other factors. The database may have reporting bias, meaning serious side effects might be reported more often than mild ones. Additionally, the study can’t determine how many patients taking these drugs experienced side effects versus how many took them without problems. Different doctors and patients may report side effects at different rates, affecting the numbers.
The Bottom Line
If you’re taking PARP inhibitors, watch for unusual fatigue changes, vitamin D deficiency, and frequent nighttime urination—report these to your doctor. If taking bevacizumab, be alert for stomach pain, blood in urine, or signs of blood clots. For immunotherapy drugs, report any unusual symptoms immediately. Most importantly, don’t stop or reduce your medication without talking to your oncologist, even if you experience side effects. Strong evidence supports monitoring for these specific signals.
Ovarian cancer patients taking these newer medications should understand these common side effects. Doctors and nurses treating ovarian cancer need this information to counsel patients and catch problems early. Family members supporting cancer patients should know what to watch for. This study is less relevant for people taking older cancer treatments or those without ovarian cancer, though some findings may apply to other cancers treated with the same drugs.
Most side effects appear within the first month of treatment, so this is the critical monitoring period. Some side effects like vitamin D deficiency develop gradually over weeks to months. Blood-related problems from combination therapy can emerge at any point during treatment. Long-term side effects may develop after months of therapy.
Frequently Asked Questions
What are the most common side effects of PARP inhibitors for ovarian cancer?
According to a 2026 analysis of 157,470 reports, the most frequently reported side effects include vitamin D deficiency, nighttime urination, unusual energy changes, increased hunger, and unintentional underdosing. Most appear within 30 days of starting treatment.
Is bevacizumab safe for ovarian cancer treatment?
Bevacizumab is effective but carries specific risks: the most reported side effects include gastrointestinal perforation, protein in urine, intestinal perforation, and blood clots. These serious complications require close medical monitoring, but benefits often outweigh risks for appropriate patients.
When do ovarian cancer drug side effects usually start?
Research shows that 85% of reported side effects appear within the first 30 days of starting medication. This critical monitoring window helps doctors catch problems early and adjust treatment if needed.
What happens when you combine different ovarian cancer drugs?
Combining bevacizumab with PARP inhibitors creates different safety concerns than either drug alone, including lung inflammation, blood cell disorders, and bone marrow problems. Doctors carefully weigh combination benefits against these additional risks.
Should I stop taking my ovarian cancer medication if I have side effects?
Never stop cancer medication without consulting your oncologist. Most side effects can be managed, reduced, or monitored without stopping treatment. Your doctor can adjust doses, add supportive medications, or modify your plan while maintaining cancer-fighting effectiveness.
Want to Apply This Research?
- Log daily energy levels (1-10 scale), nighttime bathroom trips, and any stomach discomfort. Track vitamin D test results every 3 months if on PARP inhibitors. Note any unusual bruising, bleeding, or shortness of breath immediately.
- Set daily reminders to take medication at the same time. Create a symptom checklist to review before each doctor visit. Take photos of any skin changes or swelling to show your doctor. Keep a simple log of when side effects occur relative to medication timing.
- Weekly check-ins on major side effects (energy, digestion, bleeding signs). Monthly review of patterns with your healthcare team. Quarterly lab work to catch blood cell and vitamin changes early. Immediate reporting of severe symptoms (chest pain, severe bleeding, difficulty breathing).
This analysis reviews reported side effects from a safety database but does not establish that these drugs caused specific side effects in individual cases. Side effects vary greatly between patients. This information is educational and should not replace discussions with your oncology team. All cancer treatment decisions should be made with your doctor, weighing individual benefits and risks. If you experience severe symptoms while taking cancer medications, contact your healthcare provider immediately or seek emergency care.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.